Navigation Links
Octapharma Announces octagam® 5% Again Available for U.S. Purchase
Date:11/30/2011

nked agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 28 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam® (immune globulin intravenous [human] 5%), is used to treat primary immune deficiencies, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® (Von Willebrand Factor/Coagulation Factor VIII Complex [human]) received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of Von Willebrand Disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.

Forward-looking statements

This news release contains forward-looking statements, which include known
'/>"/>

SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
2. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
3. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
4. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
5. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
9. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
10. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
11. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 The Brandeis ... Los Angeles a premier and affordable laser tattoo ... treatment special. Dr. Brandeis, focus is in providing high quality cosmetic ... to all patients. " Southern California ...
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2NuAire announces sales and service of Hitachi Koki centrifuges in North America 2
... 1, 2011 Every year thousands of children are hospitalized ... for them. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Teens share ... by colorful pills that look like candy. ... how you can prevent harm by locking your medicine up. ...
... N.J., Nov. 1, 2011 Quest Diagnostics Incorporated (NYSE: ... diagnostic testing, information and services, today announced the CE ... & RSV Direct test on the 3M™ Integrated Cycler. ... uses a proprietary technique to eliminate nucleic-acid sample extraction, ...
Cached Medicine Technology:Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 2Quest Diagnostics Announces Launch of Simplexa™ Direct Test for Influenza and Respiratory Viruses in Europe 3
(Date:4/23/2014)... WEST LAFAYETTE, Ind. - Purdue University researchers have developed ... a living cell by using tiny gold particles with ... Irudayaraj, professor of agricultural and biological engineering, used gold ... material known as BRCA1 messenger RNA splice variants, which ... The number of these mRNA splice variants in a ...
(Date:4/23/2014)... which patients might suffer potentially fatal side-effects from a ... brain scans using pattern recognition software similar to that ... developed by researchers at Imperial College London. Results of ... used the software are published in the journal ... million people each year worldwide. Ischemic strokes are the ...
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... 3 Yesterday in a historical,and unprecedented move, ... for House Bill 1150 to mandate commercial,insurance companies ... The,bill, introduced by House Speaker Dennis M. O,Brien, ... autism-related treatment for,individuals less than 21 years old., ...
... 3 Mergent, Inc., administrator for the,HealthShares(TM) Indexes, ... Exchange Traded Funds, today announced the following,change effective ... 9, 2008: ISTA,Pharmaceuticals (Nasdaq: ISTA ) will ... Ophthalmology Index. Jerini AG is being,acquired by Shire ...
... Enterprises of,Shijiazhuang, China, the world,s largest manufacturer of vinyl ... notified Medline,Industries, Inc., and other U.S. customers that they ... unable to meet their normal,agreements to customers. Hong Ray ... to supply will have a cost impact on the ...
... Details Support for Community Organizations, SOUTH PORTLAND, ... Shield donated more than $1.4 million to community ... charitable,activities are detailed in the recently released Maine ... found online at, http://www.anthem.com/maine/communityreport ., "All associates ...
... Triple-S,Management Corporation (NYSE: GTS ) today announced that ... quarter ended June 30, 2008,before the market opens on ... Officer, and Juan-Jose Roman, Finance Vice President,and Chief Financial ... and the outlook for the company at 10:00 a.m. ...
... Ro to Promote Circle of Promise ... #401, DALLAS, July 3 , WHAT: Circle of ... Brock (Dr. Ro) will bring the fight against breast cancer to ... their view on breast cancer in the ...
Cached Medicine News:Health News:Pennsylvania Tells Autism Speaks to Stop Talking 2Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index 2Health News:Medline Receives Force Majeure Notice From Hong Ray Enterprises 2Health News:Anthem Blue Cross and Blue Shield Issues Community Report for 2007 2Health News:Triple-S Management Corporation Schedules Second-Quarter Earnings Release and Webcast 2Health News:Susan G. Komen for the Cure(R)'s Circle of Promise to Mobilize African American Women Against Breast Cancer at 2008 Music Festival 2
... is a multi-tasking vacuum source and solvent ... vapor trap and a maintenance-free, oil-free vacuum ... easy-to-use, wide-mouth glass condensation flask collects all ... easy disposal. The UVS400 provides an ideal ...
... Combines BchiVac V-500 with Vacuum Controller ... Electronic switching mechanism turns V-500 on and off ... Compact Housing Model V-500 is a powerful ... applications. Applications Ideally suited for use ...
... membrane vacuum pump designed to handle most vacuum ... use with up to two rotary evaporators ... ovens, concentrators, gel dryers, and filtration apparatuses ... to chemicals and heat load Corrosion-resistant ...
... Universal Vacuum Source is a combination instrument bringing ... 4-headed, Oil-free Vacuum Pump. It is designed to ... abuse., Combines a Refrigerated Cold Trap ... eliminating extra tubing connections. , ...
Medicine Products: